Literature DB >> 15207359

Role of the calcium/calmodulin-dependent protein kinase ii (CaMKII) in the morphine-induced pharmacological effects in the mouse.

M Narita1, Y Matsumura, S Ozaki, Y Ise, Y Yajima, T Suzuki.   

Abstract

Calcium/calmodulin-dependent protein kinase II (CaMKII) is a family of multifunctional protein kinases that activates signaling pathways. The present study was designed to ascertain whether CaMKII could play a substantial role in the expression of morphine-induced antinociception, hyperlocomotion and rewarding effect in the mouse. An i.c.v. pretreatment with a CaMKII inhibitor KN-93 failed to affect the antinociception and hyperlocomotion induced by s.c. administration of a prototype micro-opioid receptor agonist morphine. In contrast, the morphine-induced place preference was significantly attenuated by i.c.v. pretreatment with KN-93. The levels of phosphorylated-CaMKII (p-CaMKII) in the limbic forebrain, but not in the frontal cortex and the lower midbrain, were significantly increased in morphine-conditioned mice, whereas the levels of CaMKII in three brain regions obtained from morphine-conditioned mice were not changed. This up-regulation of p-CaMKII in the limbic forebrain obtained from morphine-conditioned mice was significantly inhibited by i.c.v. pretreatment with KN-93. These results provide evidence that the increase in CaMKII activity in the mouse limbic forebrain may contribute to the rewarding effect, but not the antinociception and the hyperlocomotion, induced by morphine. Copyright 2004 IBRO

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207359     DOI: 10.1016/j.neuroscience.2004.03.006

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  9 in total

1.  Opiate exposure and withdrawal induces a molecular memory switch in the basolateral amygdala between ERK1/2 and CaMKIIα-dependent signaling substrates.

Authors:  Danika Lyons; Xavier de Jaeger; Laura G Rosen; Tasha Ahmad; Nicole M Lauzon; Jordan Zunder; Lique M Coolen; Walter Rushlow; Steven R Laviolette
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

2.  Opiate Exposure State Controls a D2-CaMKIIα-Dependent Memory Switch in the Amygdala-Prefrontal Cortical Circuit.

Authors:  Laura G Rosen; Jordan Zunder; Justine Renard; Jennifer Fu; Walter Rushlow; Steven R Laviolette
Journal:  Neuropsychopharmacology       Date:  2015-07-15       Impact factor: 7.853

3.  Neuroplasticity transcript profile of the ventral striatum in the extinction of opioid-induced conditioned place preference.

Authors:  Freddyson J Martínez-Rivera; Namyr A Martínez; Magdiel Martínez; Roxsana N Ayala-Pagán; Walter I Silva; Jennifer L Barreto-Estrada
Journal:  Neurobiol Learn Mem       Date:  2019-06-04       Impact factor: 2.877

4.  Impaired Acquisition of Nicotine-Induced Conditioned Place Preference in Fatty Acid-Binding Protein 3 Null Mice.

Authors:  Wenbin Jia; Gofarana Wilar; Ichiro Kawahata; An Cheng; Kohji Fukunaga
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

5.  Amyloid precursor protein mutation disrupts reproductive experience-enhanced normal cognitive development in a mouse model of Alzheimer's disease.

Authors:  Jie Cui; Balaji Jothishankar; Ping He; Matthias Staufenbiel; Yong Shen; Rena Li
Journal:  Mol Neurobiol       Date:  2013-07-14       Impact factor: 5.590

Review 6.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

7.  Reversal of prenatal morphine exposure-induced memory deficit in male but not female rats.

Authors:  Shiva Nasiraei-Moghadam; Mohammad Amin Sherafat; Mir-Shahram Safari; Fatemeh Moradi; Abolhassan Ahmadiani; Leila Dargahi
Journal:  J Mol Neurosci       Date:  2012-08-03       Impact factor: 3.444

8.  Effectiveness and Safety of Haloperidol Add-on Methadone in Acute Opium Withdrawal Symptoms of Opioid-dependent Patients: A Double-blind Randomized Placebo-controlled Clinical Trial.

Authors:  Fattaneh Ghaderi-Bafti; Mehran Zarghami; Abdolkarim Ahmadi; Mahmood Moosazadeh; Pezhman Hadinezhad; Narjes Hendouei
Journal:  Addict Health       Date:  2021-04

9.  Antagonism of the mu-delta opioid receptor heterodimer enhances opioid antinociception by activating Src and calcium/calmodulin-dependent protein kinase II signaling.

Authors:  Attila Keresztes; Keith Olson; Paul Nguyen; Marissa A Lopez-Pier; Ryan Hecksel; Natalie K Barker; Zekun Liu; Victor Hruby; John Konhilas; Paul R Langlais; John M Streicher
Journal:  Pain       Date:  2022-01-01       Impact factor: 6.961

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.